Toggle Main Menu Toggle Search

Open Access padlockePrints

An assessment of circulating biomarkers and germline genetic variants in predicting chemotherapy associated mucositis in Ewing sarcoma

Lookup NU author(s): Dr Pawan Gulati, Dr Vickyanne Carruthers, Dr Claire Hutton, Chloe Cassidy, Dr Edward Amankwatia, Séréna Pascual, Electra Florence, Professor Alastair GreystokeORCiD, Professor Gareth Veal, Dr David Jamieson

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 The AuthorsBackground: Treatment of Ewing sarcoma is associated with severe toxicities including chemotherapy-induced mucositis. Here we investigated the role of circulating biomarkers and genetic factors in predicting mucositis severity in Ewing sarcoma. Methods: Blood samples were collected from 111 Ewing sarcoma patients during treatment. Circulating total CK18 and FLT3 ligand concentrations were measured in plasma. Germline DNA was used to investigate associations between genetic variants and mucositis severity. Results: An increase in median tCK18 levels was observed during cycle 1, from 189 (86−736) U/L at cycle 1 day 1 pre-chemotherapy to 311 (141–1138) U/L on cycle 1 day 2–5 (p = 0.0001). Patients experiencing a ≥ 1.3-fold increase in tCK18 at 48–120 hours after administration of the first cycle had a higher likelihood of developing grade 3 mucositis in any cycle (p = 0.044). Genetic analysis revealed an association between a gene set associated with chemotherapy induced severe mucositis and differentially expressed genes set for minor salivary gland (p = 4.12 ×10−4) and esophageal mucosa (p = 1.55 ×10−5). Discussion: Early increases in circulating CK18 levels correlated with grade 3 mucositis. Genome-wide association analysis highlighted genes that may be associated with mucositis pathology, offering insights into biological mechanisms underlying susceptibility.


Publication metadata

Author(s): Gulati P, Carruthers V, Hutton C, Cassidy C, Amankwatia EB, Pascual S, Florence E, Gebru TG, Jorgensen AL, Greystoke A, Makin G, McCabe MG, Hawcutt DB, Veal GJ, Jamieson D

Publication type: Article

Publication status: Published

Journal: EJC Paediatric Oncology

Year: 2025

Volume: 5

Print publication date: 01/06/2025

Online publication date: 20/01/2025

Acceptance date: 14/01/2025

Date deposited: 03/02/2025

ISSN (electronic): 2772-610X

Publisher: Elsevier B.V.

URL: https://doi.org/10.1016/j.ejcped.2025.100216

DOI: 10.1016/j.ejcped.2025.100216

Data Access Statement: Supplementary data associated with this article can be found in the online version at doi:10.1016/j.ejcped.2025.100216


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
009.2014
BCRT7621
Bone Cancer Research Trust
Cancer Research UK
CTRQQR-2021\100003
ECMCQQR-2022/100002
Experimental Cancer Medicine Centre Network
Sarcoma UK

Share